

Rno	REC No	IRAS No	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
1	17/LO/0085	216434	Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects with Dialysis-Dependent Chronic Kidney Disease (DD-CKD) (INNO2VATE ? CONVERSION)	Number Agreed	1	1	Date Agreed	22/10/2018	3	22/10/2018	3	Recruitment Finished
2	17/LO/0782	227047	Placebo-Controlled Proof of Concept Study to Investigate ANB020 Activity in Adult Patients with Severe Eosinophilic Asthma	Number Agreed	8	8	Date Agreed	31/10/2018	4	31/10/2018	4	Recruitment Finished
3	18/NW/0173	242176	Effect and safety of semaglutide 2.4 mg once-weekly in subjects with overweight or obesity and type 2 diabetes	Number Agreed	8	8	Date Agreed	19/11/2018	8	19/11/2018	8	Recruitment Finished
4	16/EE/0243	207331	A 6-MONTH, MULTICENTER, PHASE 3, OPEN-LABEL EXTENSION SAFETY STUDY OF OTO-104 GIVEN AT 3-MONTH INTERVALS BY INTRATYMPANIC INJECTION IN SUBJECTS WITH UNILATERAL MENIERE'S DISEASE	Number Agreed	5	5	Date Agreed	30/11/2018	6	30/11/2018	6	Recruitment Finished
5	14/SS/1087	164169	A Phase 3b, Multi-center, Open-label Trial to Evaluate the Long Term Safety of a Titrated Immediate-release selective arginine vasopressin type 2 receptor antagonist (30 mg to 120 mg/day, Split dose) in Subjects with Autosomal Dominant Polycystic Kid	Number Agreed	1	1	Date Agreed	31/12/2018	7	31/12/2018	7	Recruitment Finished
6	16/LO/0521	191745	A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination with Tremelimumab or AZD9150 in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma	Number Agreed	1	1	Date Agreed	31/12/2018	2	31/12/2018	2	Recruitment Finished
7	13/LO/0418	112763	A multi-centre, randomised, placebo controlled double blind, two armed, parallel group study to evaluate efficacy and safety of IV Sildenafil in the treatment of neonates persistent pulmonary hypertension of the newborn (PPHN) or hypoxic respiratory	Number Agreed	1	1	Date Agreed	31/12/2018	5	31/12/2018	5	Recruitment Finished
8	16/WM/0317	206807	Randomized Efficacy and Safety Trial with Oral S44819 after recent ischaemic cerebral event.International, multi-centre, randomized, double-blind placebo-controlled phase II study.	Number Agreed	8	8	Date Agreed	31/12/2018	12	31/12/2018	12	Recruitment Finished
9	16/EM/0193	190690	A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS): The Dal-GenE trial	Number Agreed	6	6	Date Agreed	31/12/2018	8	31/12/2018	8	Recruitment Finished
10	17/LO/1068	224973	A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER TRIAL TESTING IPATASERTIB PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE RELATIVE TO PLACEBO PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE IN ADULT MALE PATIENTS WITH ASYMPTOMATIC OR M	Number Agreed	4	4	Date Agreed	31/01/2019	9	31/01/2019	9	Recruitment Finished
11	15/YH/0478	186697	A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis	Number Agreed	8	8	Date Agreed	31/01/2019	0	31/01/2019	0	Withdrawn By Sponsor

Rno	REC No	IRAS No	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
12	17/SC/0016	218645	A Phase III, Randomized, Open Label Trial of Nivolumab in combination with Ipilimumab versus Pemetrexed with Cisplatin or Carboplatin as First Line Therapy in unresectable Pleural Mesothelioma	Number Agreed	6	6	Date Agreed	28/02/2019	8	28/02/2019	8	Recruitment Finished
13	16/EM/0422	209463	A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of mepolizumab in the treatment of adolescent and adult subjects with severe hypereosinophilic syndrome	Number Agreed	2	2	Date Agreed	01/03/2019	6	01/03/2019	6	Recruitment Finished
14	18/LO/0416	235395	A Phase 1b/2 Study to Evaluate Safety and Anti-tumour Activity of Avelumab in Combination with the Poly (Adenosine Diphosphate [ADP]-Ribose) Polymerase (PARP) Inhibitor Talazoparib in Patients with Locally Advanced or Metastatic Solid Tumours.	Number Agreed	5	5	Date Agreed	31/03/2019	3	31/03/2019	3	Recruitment Finished
15	14/LO/1486	159398	A Phase 1b/2, Multicenter, Open-label Trial of Talimogene Laherparepvec in Combination with MK-3475 for Treatment of Previously Untreated, Unresected, Stage IIIB to IVM1c Melanoma (MASTERKEY-265)	Number Agreed	5	5	Date Agreed	10/04/2019	2	10/04/2019	2	Recruitment Finished
16	17/NE/0115	218417	Phase II study of Pirfenidone vs placebo in patients with fibrotic ILD that cannot be classified with moderate or high confidence into any other category of fibrotic IP by Multidisciplinary Team (MDT) review (?unclassifiable? ILD).	Number Agreed	2	2	Date Agreed	14/04/2019	2	14/04/2019	2	Recruitment Finished
17	16/LO/0422	198606	A Phase I trial of oral CCT245737 (a CHK1 inhibitor) given in combination with gemcitabine plus cisplatin or gemcitabine alone in patients with advanced cancer	Number Agreed	5	5	Date Agreed	30/04/2019	5	30/04/2019	5	Recruitment Finished
18	17/LO/1451	229939	A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control on Basal Insulin Alone or in Addition	Number Agreed	5	5	Date Agreed	17/05/2019	0	17/05/2019	0	Withdrawn By Sponsor
19	15/SW/0194	185459	A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven phase 3 study to investigate the efficacy of finerenone on the progression of deterioration of kidney function in patients with type 2 diabetes mellitus and the	Number Agreed	5	5	Date Agreed	29/05/2019	4	29/05/2019	4	Recruitment Finished
20	17/WS/0072	221444	EDOXABAN VERSUS STANDARD OF CARE AND THEIR EFFECTS ON CLINICAL OUTCOMES IN PATIENTS HAVING UNDERGONE TRANSCATHETER AORTIC VALVE IMPLANTATION ? IN ATRIAL FIBRILLATION	Not Available / Not Agreed			Date Agreed	31/05/2019	0	31/05/2019	0	Withdrawn By Sponsor
21	18/LO/1301	249407	VIVO Accuracy Study	Number Agreed	6	6	Date Agreed	14/06/2019	6	14/06/2019	6	Recruitment Finished
22	16/LO/0797	199957	A Phase 3, 2 Part, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who are Less than 24 Months of Age at Treatment Initiation and Have a CFTR Gating Mutation	Number Agreed	1	1	Date Agreed	19/06/2019	0	19/06/2019	0	Recruitment Finished

Rno	REC No	IRAS No	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
23	17/SW/0221	232448	A randomized, partially-blinded, active-controlled, multicenter study of secukinumab to demonstrate reduction of radiographic progression versus GP2017 (adalimumab biosimilar) at 104 weeks and to assess the long term safety, tolerability and efficacy	Number Agreed	4	4	Date Agreed	27/06/2019	1	27/06/2019	1	Recruitment Finished
24	17/YH/0432	236091	A double blind (sponsor open) placebo-controlled, stratified, parallel group study to evaluate the efficacy and safety of repeat doses of GSK3772847 in participants with moderate to severe asthma with allergic fungal airway disease (AFAD).	Number Agreed	3	3	Date Agreed	28/06/2019	2	28/06/2019	2	Recruitment Finished
25	17/EM/0367	231327	A multi-centre, open-label extension, safety study to describe the longterm clinical experience of mepolizumab in participants with hypereosinophilic syndrome (HES) from Study 200622	Number Agreed	4	4	Date Agreed	06/08/2019	6	06/08/2019	6	Recruitment Finished
26	16/NW/0621	206740	Phase 3, randomized, open-label, active-controlled study evaluating the efficacy and safety of oral vadadustat for the maintenance treatment of anemia in subjects with non-dialysis-dependent chronic kidney disease (NDD-CKD) (PRO2TECT-CONVERSION)	Number Agreed	2	2	Date Agreed	30/08/2019	0	30/08/2019	0	Recruitment Finished
27	18/EE/0197	246434	A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)	Number Agreed	5	5	Date Agreed	31/08/2019	2	31/08/2019	2	Recruitment Finished
28	17/LO/0041	219676	CardioMEMS OUS	Number Agreed	10	10	Date Agreed	01/09/2019	16	01/09/2019	16	Recruitment Finished
29	12/NW/0694	109044	A 12 week randomised, open-label, active control period followed by a 12 week safety extension period to evaluate the safety and efficacy of Fesoteridine in subjects aged 6 to 16 years and >25kg with symptoms of detrusor overactivity associated with a	Number Agreed	2	2	Date Agreed	31/03/2019	1	31/03/2019	1	Recruitment Finished
30	16/EE/0183	199109	Efficacy and safety of BI 655064 in patients with active lupus nephritis	Number Agreed	1	1	Date Agreed	30/06/2019	0	30/06/2019	0	Withdrawn By Sponsor
31	16/NW/0620	206738	Phase 3, randomized, open-label, active-controlled study evaluating the efficacy and safety of oral vadadustat for the correction of anemia in subjects with non-dialysis-dependent chronic kidney disease (NDD-CKD) (PRO2TECTCORRECTION)	Number Agreed	2	2	Date Agreed	30/08/2019	0	30/08/2019	0	Withdrawn By Sponsor
32	16/EE/0196	201273	CHIL 5025, A 24 Week Multicenter, Randomized, Double-Blind, Parallel Group, Phase 3 Trial with a 28 Week Long Term Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 10mg in T2DM Patients aged 10 - 24 years.?	Number Agreed	2	2	Date Agreed	24/09/2019	1	24/09/2019	1	Recruitment Finished